USA: new law promises $100 million for ALS research

A new law has been passed in the United States to give…

Av Lucie van Leeuwen.Publicerad January 13, 2022
USA: new law promises $100 million for ALS research

A new law has been passed in the United States to give more people with ALS access to experimental treatments. The government is also pledging $100 million a year for research into new treatments over the next five years.

Only a small proportion of people with ALS participate in clinical trials. This happens for various reasons. For example, many studies still use restrictive entry criteria, denying many people with ALS access to clinical trials. For other people, participation might  be physically too challenging. One of TRICALS’ goals is therefore to make trials accessible for everyone living with ALS. The new American law, called Accelerating Access to Clinical Therapies (ACT) for ALS, will make money available to give more people access to experimental treatments.

The passing of the ACT for ALS bill would not have been possible without the commitment and determination of thousands of ALS advocates. They have worked together and campaigned tirelessly to get the ACT for ALS on the political agenda. With success: on December 23rd, President Biden signed the bill into law.

ACT for ALS

ACT for ALS contains four components:

  • Grants for research on therapies for ALS
    Funding will be available so that people with ALS, who for reasons cannot participate in the clinical trial, may still get access to investigational ALS treatments. This applies to drugs being tested in phase 3 clinical trials.
  • Public-Private Research Partnerships
    The aim is to encourage collaborations between the government and private companies, universities and other research institutes. These collaborations should accelerate research into ALS and other neurodegenerative diseases.
  • FDA Grant Program
    An FDA (U.S. Food and Drug Administration) funding program for research into ALS and related conditions. The funding is mainly intended for projects aiming to learn how these conditions progress, discover new drug targets and improving clinical trial design.
  • Publication of action plan
    The FDA must publish an action plan within six months, outlining how they will accelerate drug development and increase access to investigational therapies.

More information about the ACT for ALS law can be found on the website of I AM ALS.


Dela
Nuvarande prövningar
Recruiting
Fas iii

COURAGE-ALS Studie

Företagsinitierad prövning
Med COURAGE-ALS studie undersöker vi verkningarna och säkerheten för medlet reldesemtiv för behandling av ALS. Denna läkemedelsundersökning genomförs på uppdrag av Cytokinetics.
Läs mer
Recruiting
Fas iii

PHOENIX studie

Företagsinitierad prövning
Amylyx Pharmaceuticals Inc utför en fas 3-studie för att fastställa säkerheten och effektiviteten av deras förening 'AMX0035' för behandling av SLA.
Läs mer
Recruiting
Fas iii

ADORE Studie

Företagsinitierad prövning
Ferrer håller på att utföra en fas 3-studie för att bedöma säkerheten och den potentiella effektiviteten av ett prövningsläkemedel för personer med Amyotrofisk lateralskleros (SLA).
Läs mer
Recruiting
Fas ii

APL2-ALS-206-studie

I denna fas 2-studie undersöker vi säkerheten och effekten hos läkemedlet pegcetacoplan för behandling av ALS. Den här läkemedelsundersökningen har utformats på uppdrag av Apellis Pharmaceuticals.
Läs mer
Active
Fas ii

RT001 vid amyotrofisk lateralskleros

I denna fas II-studie vill vi studera säkerhet och effektivitet av sammansättningen RT001 hos personer som lever med ALS. Denna kliniska studie sponsras av Retrotope Inc.
Läs mer

Relaterade nyheter

Congratulations to our TRICALS colleagues as UK Government invests £50 million to find a cure for ALS
Congratulations to our TRICALS colleagues as UK Government invests £50 million to find a cure for ALS
The UK government has recently announced that £50 million will be invested […]
A road map for digital health care technology in MND
A road map for digital health care technology in MND
The COVID-19 pandemic has had an important impact on the development and […]
Amylyx Pharmaceuticals and TRICALS to collaborate on phase 3 clinical trial
Amylyx Pharmaceuticals and TRICALS to collaborate on phase 3 clinical trial
Today, Amylyx Pharmaceuticals provided an update on its plans to advance its […]
Newsletter December 2020
Newsletter December 2020
2020 has been a difficult year for everyone. However, despite the many […]